Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Maze Therapeutics, Inc.NASDAQ: MAZE
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow turns positive
Q1 FY2026 investing cash flow was $6.28M, compared with -$299K a year earlier. Trailing-twelve-month investing cash flow was -$164.39M. Over 3 fiscal years it compounded at +277.8% a year.
Context
- Investing cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly investing cash flow holds near $6.28M or moves back toward the trailing-twelve-month quarterly average of -$41.1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (170.96M) USD
- Year-over-year change
- -14805.1%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (170.96M) | -14805.1% |
| FY2024 | 2024-12-31 | (1.15M) | -160.1% |
| FY2023 | 2023-12-31 | (441K) | +86.1% |
| FY2022 | 2022-12-31 | (3.17M) | — |
Investing Cash Flow vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13986.4% is the highest of 8, against a peer median of -18.3%.
- Investing cash flow amounts to 821.9% of revenue for MAZE, versus a peer median of 113.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $471.91M USD | +23.8% | — | 46.8% | |
| LTM Sep 2026 | $409.2M USD | -880.6% | — | 62.9% | |
| LTM Mar 2026 | $164.39M USD | +13986.4% | +277.8% | 821.9% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $157.22M USD | -11.3% | +462.4% | 163.3% |
| FY2025 | €127.93M EUR | -1562.9% | — | 2853.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $63.98M USD | -18.3% | +874.1% | 620.2% |
| LTM Mar 2026 | $21.81M USD | +69.1% | — | 5.1% | |
| LTM Mar 2026 | $11.37M USD | -203.5% | — | — | |
| Peer median (excluding MAZE) | — | -18.3% | +668.3% | 113.1% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.